The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 16, 2020

Filed:

Apr. 03, 2018
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventors:

Alan List, Tampa, FL (US);

Sheng Wei, Tampa, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); A61K 31/711 (2006.01); A61K 38/00 (2006.01); A61K 31/454 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
A61K 47/54 (2017.08); A61K 31/454 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); A61K 47/549 (2017.08); C12N 15/1137 (2013.01); C12Y 301/03016 (2013.01); C12Y 301/03048 (2013.01); C12N 2310/14 (2013.01);
Abstract

Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.


Find Patent Forward Citations

Loading…